Abstract:Although a clear mechanism underlying the pathophysiology of schizophrenia (SZ) remains elusive, oxidative stress, inflammatory syndrome and immune activation have become an attractive hypothesis for explaining the pathophysiology of SZ. Data from prior studies on the role of matrix metalloproteinase 9 (MMP-9) and brain-derived neurotrophic factor (BDNF) single nucleotide polymorphisms (SNPs) in SZ are contradictory. We aimed to investigate whether oxidative stress, inflammatory and immune activation markers as well as MMP-9 levels may be implicated in SZ pathogenesis. The association of MMP-9 and BDNF SNPs with the clinical expression of SZ was examined.Ninety-four subjects were recruited, including 44 SZ patients and 50 healthy controls. Serum levels of thiobarbituric acid reactive substances (TBARS), protein carbonyl content (PCC), nitrite, C-reactive protein (CRP), interleukin 6 (IL-6), tumor necrosis factor alpha (TNF-α), Beta-2 microglobulin (Β2M), complement component 3 (C3), C4 and MMP-9 were measured. The MMP-9 − 1562C > T and BDNF196G > A SNPs were genotyped using polymerase chain reaction-restriction fragment length polymorphism assay. Psychopathology was assessed using the positive and negative syndrome scale (PANSS).SZ patients showed significantly higher TBARS, PCC, nitrite, CRP, IL-6, TNF-α, Β2M, C3 and MMP-9 levels than controls. In distinguishing SZ patients from healthy controls, CRP and MMP-9 yielded similar discriminatory performance, and both perform better than IL-6, Β2M, C3, nitrite, TBARS, PCC, TNF-α and C4. The MMP-9 − 1562C > T SNP genotypes distribution didn't differ significantly between controls and SZ patients. As compared to controls, SZ patients harbor a significantly higher frequency of the BDNF196GG genotype and a lower frequency of the BDNF196GA/AA genotype. Patients carrying the MMP-9 − 1562CC or BDNF196GG genotype revealed a significantly higher PANSS than those carrying MMP-9 − 1562CT/TT or BDNF196GA/AA genotype. Male gender and the MMP-9 − 1562CC genotype were identified as independent predictive factors for higher PANSS.Redox dysregulation and alterations in the immuno-inflammatory pathways are major culprits in the pathogenesis of SZ. MMP-9 and BDNF SNPs are associated with the clinical phenotype of SZ and, thus, may be a useful marker predicting the phenotypic expression and prognosis of SZ patients.

High Mobility Group Protein 1 and Dickkopf-Related Protein 1 in Schizophrenia and Treatment-Resistant Schizophrenia: Associations with Interleukin-6, Symptom Domains, and Neurocognitive Impairments

Linking peripheral IL-6, IL-1 and hypocretin-1 with cognitive impairment from major depression

Differences in Inflammatory Marker Profiles and Cognitive Functioning Between Deficit and Nondeficit Schizophrenia

The C(−1562)T Polymorphism of Matrix Metalloproteinase-9 Gene is Associated with Schizophrenia in China

The Interleukin-6/Interleukin-23/t Helper 17-Axis As a Driver of Neuro-Immune Toxicity in the Major Neurocognitive Psychosis or Deficit Schizophrenia: A Precision Nomothetic Psychiatry Analysis.

The Neuroimmune and Neurotoxic Fingerprint of Major Neurocognitive Psychosis or Deficit Schizophrenia: a Supervised Machine Learning Study

In Schizophrenia, Immune-Inflammatory Pathways Are Strongly Associated with Depressive and Anxiety Symptoms, Which Are Part of a Latent Trait Which Comprises Neurocognitive Impairments and Schizophrenia Symptoms.

Associations between cytokine levels and cognitive function among individuals at clinical high risk for psychosis

Alterations in innate immune defense distinguish first-episode schizophrenia patients from healthy controls

High Predictive Value of Immune-Inflammatory Biomarkers for Schizophrenia Diagnosis and Association with Treatment Resistance

A new schizophrenia model: immune activation is associated with induction of different neurotoxic products which together determine memory impairments and schizophrenia symptom dimensions.

Immunoinflammatory features and cognitive function in treatment-resistant schizophrenia: unraveling distinct patterns in clozapine-resistant patients

The Inflammatory Response System in Treatment-Resistant Schizophrenia: Increased Serum Interleukin-6

The Endogenous Opioid System in Schizophrenia and Treatment Resistant Schizophrenia: Increased Plasma Endomorphin 2, and Κ and Μ Opioid Receptors Are Associated with Interleukin-6

Supervised Machine Learning to Decipher the Complex Associations Between Neuro-Immune Biomarkers and Quality of Life in Schizophrenia

A new schizophrenia model: immune activation is associated with induction of the tryptophan catabolite pathway and increased eotaxin levels which together determine memory impairments and schizophrenia symptom dimensions.

Contribution of IL-10 and Its -592 A/C Polymorphism to Cognitive Functions in First-Episode Drug-Naive Schizophrenia

Plasma levels of IL-1Ra is associated with schizophrenia.

In Schizophrenia, Psychomotor Retardation is Associated with Executive and Memory Impairments, Negative and Psychotic Symptoms, Neurotoxic Immune Products and Lower Natural IgM to Malondialdehyde

In Schizophrenia, the Effects of the IL-6/IL-23/Th17 Axis on Health-Related Quality of Life and Disabilities Are Partly Mediated by Generalized Cognitive Decline and the Symptomatome.

Ndt_a_218483 191..199